Oral and ocular administration of crocetin prevents retinal edema in a murine retinal vein occlusion model.
Administration, Ophthalmic
Administration, Oral
Animals
Carotenoids
/ administration & dosage
Disease Models, Animal
Edema
/ complications
Inflammation Mediators
/ metabolism
Male
Matrix Metalloproteinase 9
/ metabolism
Mice
Occludin
/ metabolism
Ophthalmic Solutions
/ administration & dosage
Retina
/ pathology
Retinal Vein Occlusion
/ complications
Tight Junctions
/ drug effects
Tumor Necrosis Factor-alpha
/ metabolism
Vitamin A
/ analogs & derivatives
Journal
Molecular vision
ISSN: 1090-0535
Titre abrégé: Mol Vis
Pays: United States
ID NLM: 9605351
Informations de publication
Date de publication:
2019
2019
Historique:
received:
22
10
2018
accepted:
23
12
2019
entrez:
8
1
2020
pubmed:
8
1
2020
medline:
20
6
2020
Statut:
epublish
Résumé
We investigated the effects of oral and ocular administration of crocetin in a murine retinal vein occlusion (RVO) model. Crocetin is a type of carotenoid contained in the fruit of gardenia ( This study was performed on a murine RVO model, which was created by laser irradiation of retinal veins. We evaluated the retinal thickness after the oral administration of crocetin (100 mg/kg) 1 and 6 h before laser irradiation, and immediately, 6 h, 12 h, and 18 h after laser irradiation in the murine RVO model. In addition, we measured the retinal layer thickness after administration of crocetin eye drops (0.03% or 0.10%) immediately, 6 h, and 12 h after laser irradiation. Western blotting of retinal tissue was used to determine the expression levels of matrix metalloproteinase (MMP-9), tumor nuclear factor (TNF-α), and occludin after oral administration of crocetin. Oral and ocular administration of crocetin improved retinal edema in the murine RVO model. Crocetin administration statistically significantly suppressed overexpression of MMP-9 and TNF-α, and reversed the reduction of occludin. These findings indicate that crocetin can protect retinal tight junctions by suppressing retinal edema through an anti-inflammatory effect, which suggests that crocetin may be useful for RVO disease.
Substances chimiques
Inflammation Mediators
0
Occludin
0
Ophthalmic Solutions
0
Tumor Necrosis Factor-alpha
0
trans-sodium crocetinate
0
Vitamin A
11103-57-4
Carotenoids
36-88-4
Matrix Metalloproteinase 9
EC 3.4.24.35
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
859-868Informations de copyright
Copyright © 2019 Molecular Vision.
Références
Pharmazie. 2006 Apr;61(4):348-52
pubmed: 16649553
Molecules. 2008 Dec 03;13(12):2975-85
pubmed: 19052522
Diabetes. 2010 Sep;59(9):2297-305
pubmed: 20530741
Acta Ophthalmol. 2013 Sep;91(6):540-6
pubmed: 23171290
Eur J Pharmacol. 2012 Jan 15;674(2-3):391-6
pubmed: 21925167
J Pharmacol Sci. 2018 Jun;137(2):129-136
pubmed: 29983234
Eur J Pharmacol. 2010 Sep 10;642(1-3):77-85
pubmed: 20553915
Invest Ophthalmol Vis Sci. 2011 Apr 05;52(5):2160-4
pubmed: 21178141
Int J Inflam. 2013;2013:438412
pubmed: 23653882
Planta Med. 2011 Jan;77(2):146-51
pubmed: 20803418
Brain Res. 2007 Mar 23;1138:86-94
pubmed: 17274961
Am J Physiol Heart Circ Physiol. 2005 Aug;289(2):H558-68
pubmed: 15764676
Ophthalmology. 2010 Jun;117(6):1124-1133.e1
pubmed: 20381871
Eye (Lond). 2010 Nov;24(11):1692-9
pubmed: 20847749
Eur J Pharmacol. 2012 Sep 5;690(1-3):84-9
pubmed: 22760072
Invest Ophthalmol Vis Sci. 2011 Sep 21;52(10):7289-97
pubmed: 21849425
Am J Pathol. 2000 May;156(5):1733-9
pubmed: 10793084
J Cell Biol. 2015 May 25;209(4):493-506
pubmed: 26008742
Curr Neurovasc Res. 2012 May;9(2):102-9
pubmed: 22475394
Am J Physiol Lung Cell Mol Physiol. 2001 Dec;281(6):L1444-52
pubmed: 11704541
Eye (Lond). 2014 Sep;28(9):1095-9
pubmed: 24946846
Arterioscler Thromb Vasc Biol. 2011 May;31(5):1041-8
pubmed: 21293011
Expert Rev Clin Pharmacol. 2018 Sep;11(9):903-916
pubmed: 30071180
Biochem Cell Biol. 2014 Apr;92(2):105-11
pubmed: 24697694
Biochim Biophys Acta. 2008 Mar;1778(3):794-809
pubmed: 17961505
Diabetes. 1999 May;48(5):1131-7
pubmed: 10331420
Eur J Pharmacol. 2013 Mar 5;703(1-3):1-10
pubmed: 23428630
Invest Ophthalmol Vis Sci. 2001 Mar;42(3):853-9
pubmed: 11222550
Sci Rep. 2017 Mar 02;7:43509
pubmed: 28252108
J Pharmacol Sci. 2017 Jun;134(2):86-92
pubmed: 28619445
Eur J Pharmacol. 2011 Jan 10;650(1):110-9
pubmed: 20951131
Neurosurg Focus. 2007 May 15;22(5):E4
pubmed: 17613235
Invest Ophthalmol Vis Sci. 2018 Sep 4;59(11):4701-4713
pubmed: 30267092
PLoS One. 2009 Dec 04;4(12):e8158
pubmed: 19997642
J Clin Biochem Nutr. 2011 Nov;49(3):182-7
pubmed: 22128217
Clin Ophthalmol. 2010 Jul 30;4:809-16
pubmed: 20689798
Thromb Haemost. 2001 Jul;86(1):308-15
pubmed: 11487019
J Control Release. 2009 Jun 19;136(3):247-53
pubmed: 19272407
JAMA Ophthalmol. 2013 Feb;131(2):160-5
pubmed: 23411880
Ophthalmology. 2010 Feb;117(2):313-9.e1
pubmed: 20022117
Pharmacol Res. 2006 Oct;54(4):268-74
pubmed: 16899372
J Biol Chem. 1999 Aug 13;274(33):23463-7
pubmed: 10438525
Clin Ophthalmol. 2008 Dec;2(4):919-30
pubmed: 19668445
Am J Physiol Lung Cell Mol Physiol. 2007 Mar;292(3):L799-812
pubmed: 17158602
Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18751-6
pubmed: 19841260
Am J Ophthalmol. 2013 Oct;156(4):693-705
pubmed: 24053892
Lab Invest. 2005 May;85(5):597-607
pubmed: 15711567
Eur J Pharmacol. 2016 Oct 15;789:244-253
pubmed: 27452919
Ophthalmology. 2016 Mar;123(3):625-34.e1
pubmed: 26712560
Eur J Pharmacol. 2010 Dec 1;648(1-3):110-6
pubmed: 20854811
Cell Physiol Biochem. 2016;40(3-4):443-452
pubmed: 27889767